About Creavo
About
Creavo
A vision to transform cardiology
We believe our technology has the power to transform the way that heart disease is identified and subsequently treated. Through our ground breaking MCG technology, we aim to reduce the economic burden on healthcare systems worldwide.
A vision to transform cardiology
We believe our technology has the power to transform the way that heart disease is identified and subsequently treated. Through our ground breaking MCG technology, we aim to reduce the economic burden on healthcare systems worldwide.
Timeline of Key Achievements
April 2014
Company created as a spin out from the University of Leeds with initial £1.6m “seed funding”
February 2015
60 60 clinical study completed at Leeds
July 2015
£4.6m raised in Series A funding round
February 2016
Company received ISO 13485
November 2016
Creavo's research device receives CE mark
January 2017
Start of 750 patient, multi-site effectiveness study in five major UK ED's
May 2017
£13.4m raised in Series B funding round
Oct 2017
Creavo's research device receives FDA 510(k) approval
July 2018
Start of 720 patient, multi-site effectiveness study in five major US healthcare research facilities
Meet the board
Robert Barr
Chairman of the Board
Steve Parker
Chief Executive Officer
Andrew Mullen
Operations Director
Prof Ben Varcoe
Chief Scientific Officer
Chris Meredith
Non Executive Director Test
Craig Richardson
Non Executive Director
Pierre Chauvineau
Non Executive Director
Meet the medical advisory board
Dr Richard Charles
Chair Medical Advisory Board
Prof John Camm
Board Member
Dr Robert Henderson
Board Member
Prof Rod Stables
Board Member
Dr Francis Morris
Board Member
Dr Faizel Osman
Board Member
Awards
Send us your enquiry
To find out more about Creavo, our ongoing clinical work or our international commercial collaborations please complete the following form:
Registered Address
Creavo Medical Technologies Limited
CEL House Westwood Way
Westwood Business Park
Coventry
CV4 8HS